Expert Interview
Examining the potential of Calithera’s advanced clear cell RCC therapy, telaglenastat (CB-839)
Ticker(s): CALAAn oncologist with clinical practice experience in Renal Cell Carcinoma and knowledge about Calithera’s pipeline targeting advanced clear cell RCC.
Please tell us about your clinical experience. How many patients do you treat with Renal Cell Carcinoma, and what percentage of your patients have been treated with at least two prior lines of systemic therapy?
Added By: catalin_adminWhat % of the patients benefit from VEGFR-targeted tyrosine kinase inhibitor? How many fail VEGFR therapy?
Added By: catalin_adminThe company’s main drug, telaglenastat, when added to everolimus, doubled the median PFS in heavily pretreated patients with advanced RCC to 3.8 months as compared to 1.9 months for everolimus alone. How satisfactory is this result, judging from your clinical experience?
Added By: catalin_adminWhat are some of the unmet needs still present in the space of Renal Cell Carcinoma? What role can Glutaminase Inhibitors like Telaglenastat play as 3rd line therapy?
Added By: catalin_adminPlease comment on the reduced risk of disease progression or death by 36% (HR=0.64, p=0.079 one-sided) in P2 ENTRATA study. What is your opinion on the results?
Added By: catalin_adminWhat kind of results would you like to see in order to be convinced of the drug’s efficacy?What is your impression about the fact that secondary endpoint of overall survival is has not yet produced results. What should we expect?
How likely would you be to switch your patients to Telaglenastat?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
